Home Cart Sign in  
Chemical Structure| 259793-96-9 Chemical Structure| 259793-96-9

Structure of Favipiravir
CAS No.: 259793-96-9

Chemical Structure| 259793-96-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Favipiravir is an anti-viral compound with activity against many RNA viruses and an RNA-directed RNA polymerase NS5B inhibitor.

Synonyms: T-705; Favilavir; Avigan

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Frauke Assmus ; Jean-Sélim Driouich ; Rana Abdelnabi ; Laura Vangeel ; Franck Touret ; Ayorinde Adehin , et al.

Abstract: In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs (e.g., remdesivir, dexamethasone, tocilizumab, baricitinib), others failed to show clinical efficacy. One reason is the lack of clear translational processes based on adequate preclinical profiling before clinical evaluation. Combined with limitations of existing in vitro and in vivo models, there is a need for a systematic approach to urgent antiviral drug development in the context of a global pandemic. We implemented a methodology to test repurposed and experimental drugs to generate robust preclinical evidence for further clinical development. This translational drug development platform comprises in vitro, ex vivo, and in vivo models of SARS-CoV-2, along with pharmacokinetic modeling and simulation approaches to evaluate exposure levels in plasma and target organs. Here, we provide examples of identified repurposed antiviral drugs tested within our multidisciplinary collaboration to highlight lessons learned in urgent antiviral drug development during the COVID-19 pandemic. Our data confirm the importance of assessing in vitro and in vivo potency in multiple assays to boost the translatability of pre-clinical data. The value of pharmacokinetic modeling and simulations for compound prioritization is also discussed. We advocate the need for a standardized translational drug development platform for mild-to-moderate COVID-19 to generate preclinical evidence in support of clinical trials. We propose clear prerequisites for progression of drug candidates for repurposing into clinical trials. Further research is needed to gain a deeper understanding of the scope and limitations of the presented translational drug development platform.

Keywords: COVID-19 ; drug repurposing ; translational medicine ; pandemics ; clinical trials

Purchased from AmBeed: ; ; ; ; ; ; ; ; 61718-82-9

Alternative Products

Product Details of Favipiravir

CAS No. :259793-96-9
Formula : C5H4FN3O2
M.W : 157.10
SMILES Code : O=C(C1=NC(F)=CNC1=O)N
Synonyms :
T-705; Favilavir; Avigan
MDL No. :MFCD16879084
InChI Key :ZCGNOVWYSGBHAU-UHFFFAOYSA-N
Pubchem ID :492405

Safety of Favipiravir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Related Pathways of Favipiravir

DNA

Isoform Comparison

Biological Activity

Target
  • RdRp

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01728753 Influenza Phase 1 Phase 2 Completed - United States, Florida ... More >> Miami Research Associates Miami, Florida, United States, 33143 Less <<
NCT02662855 Ebola Virus Disease Phase 2 Completed - -
NCT01068912 Influenza Phase 2 Completed - -
NCT02008344 Influenza Phase 3 Completed - -
NCT02026349 Influenza Phase 3 Completed - -
NCT02739477 Ebola Virus Survivor PHASE2 TERMINATED 2025-08-16 Conakry, Conakry, Guinea|Nzéré... More >>koré, Nzérékoré, Guinea Less <<
NCT03394209 Influenza, Human ... More >> Critical Illness Influenza Less << Phase 2 Recruiting December 10, 2018 China ... More >> China-Japan Friendship Hospital Recruiting Beijing, China, 100029 Contact: Bin Cao, Ph.D    86 010 84206264    caobin_ben@163.com    Contact: Yeming Wang, Ph.D    86 18810663558    wwyymm_love@163.com    Principal Investigator: Bin Cao, Ph.D Less <<
NCT02329054 Ebola Virus Disease PHASE2 COMPLETED 2025-09-15 The caregivers treatment cente... More >>r, Conakry, Guinea|MSF Ebola treatment centre, Gueckedou, Guinea|French Red Cross Ebola care center, Macenta, Guinea|ALIMA Ebola care center, Nzerekore, Guinea Less <<
NCT01068912 - Completed - -
NCT01419457 Healthy Hepat... More >>ic Impairment Less << Phase 1 Completed - United States, Florida ... More >> University of Miami Miami, Florida, United States Orlando Clinical Research Center Orlando, Florida, United States Less <<
NCT04818320 Covid19 PHASE3 COMPLETED 2021-07-13 Penang General Hospital, Georg... More >>e Town, Pulau Pinang, 10450, Malaysia Less <<
NCT04333589 COVID-19 UNKNOWN 2020-09-15 The Second People's Hospital o... More >>f Fuyang, Fuyang, Anhui, 230022, China|Ezhou Hospital of Traditional Chinese Medicine, Ezhou, Hubei, 436000, China|Ezhou Central Hospital, Wuhan, Hubei, 430000, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, 430000, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, 430000, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, 430000, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430000, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, 325000, China Less <<
NCT04474457 COVID-19 UNKNOWN 2021-06-01 Hacettepe University, School o... More >>f Medicine, Ankara, Turkey Less <<
NCT04445467 COVID PHASE2 UNKNOWN 2025-12-21 Alfred Health, Melbourne, Vict... More >>oria, 3004, Australia Less <<
NCT04600999 SARS-CoV-2 Infection PHASE3 COMPLETED 2020-12-28 Department of Pulmonology Semm... More >>elweis University, Budapest, 1083, Hungary|National Korányi Institute for Pulmonology, Budapest, 1121, Hungary|Institute of Infectology, University of Debrecen, Debrecen, 4031, Hungary|1st Department of Medicine, University of Pécs, Pécs, 7624, Hungary|First Department of Internal Medicine, University of Szeged, Szeged, 6720, Hungary Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

6.37mL

1.27mL

0.64mL

31.83mL

6.37mL

3.18mL

63.65mL

12.73mL

6.37mL

References

 

Historical Records

Categories